IDXX

As of 2026-09-10, IDXX scores 46out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. IDXX trades at $506.53, 45% above the band ceiling.

IDXX scores 46 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 46. Its strongest factor is quality at 68 (strong), where earnings quality and balance-sheet strength stand out, followed by value at 55. The weakest is momentum at 22, where price trend is the soft spot. Among Healthcare stocks it sits in the lower 49% of Healthcare names by composite.

On valuation, IDXX is priced near the top of its recent range — the rich end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 47. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on IDXX, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where IDXX sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for IDXX runs $257.69–$350.15. Current price $506.53 sits 45% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.